Value Based Payment Background Paper

November 29, 2017

Duke-Margolis has formed a first-of-its-kind consortium to address key practical issues in advancing value-based payment arrangements for pharmaceuticals, medical devices, and innovative gene technologies. The consortium will develop approaches and policies that support better outcomes for patients and better value across the system.

The consortium was formed to address rising concerns over a medical product pipeline with many innovative and potentially curative therapies that also raise concerns about rising costs and the relationship between pricing and value.